Table 5.
The adjusted risk of death among recipients aged ≥ 60 years, stratified by donor/recipient risk groups
| High-Immunologic-Risk Recipient |
Low-Immunologic-Risk Recipient |
|||
|---|---|---|---|---|
| High-Risk Donora (n = 2849) | Low-Risk Donorb (n = 3155) | High-Risk Donorc (n = 4468) | Low-Risk Donord (n = 4348) | |
| rATG, n | 1522 | 1721 | 2120 | 1777 |
| Alemtuzumab, n | 401 | 245 | 466 | 353 |
| IL2RA, n | 926 | 1189 | 1882 | 2218 |
| Death | ||||
| rATG | 1.00 | 1.00 | 1.00 | 1.00 |
| alemtuzumab | 1.65 (1.27 to 2.16) | 1.16 (0.81 to 1.66) | 1.60 (1.23 to 2.06) | 0.83 (0.58 to 1.18) |
| IL2RA | 1.16 (0.96 to 1.41) | 1.08 (0.91 to 1.28) | 1.15 (0.99 to 1.34) | 1.03 (0.88 to 1.20) |
| Recipient age <70 years | 0.57 (0.47 to 0.70) | 0.79 (0.65 to 0.98) | 0.78 (0.67 to 0.90) | 0.63 (0.54 to 0.74) |
| Black recipient race | 0.86 (0.71 to 1.03) | 0.86 (0.73 to 1.02) | – | – |
| PRA > 20 | NS | NS | – | – |
| Dialysis duration >3 years | 1.41 (1.17 to 1.69) | 1.48 (1.08 to 1.73) | 1.34 (1.17 to 1.54) | 1.25 (1.08 to 1.45) |
| ESRD from diabetes mellitus | 1.40 (1.11 to 1.77) | 1.26 (1.03 to 1.55) | 1.20 (1.01 to 1.43) | 1.59 (1.34 to 1.87) |
| Tacrolimus use at discharge | 0.77 (0.57 to 1.04) | 0.78 (0.65 to 0.92) | 0.85 (0.74 to 0.99) | 0.81 (0.70 to 0.95) |
| MPA use at discharge | 0.75 (0.61 to 0.92) | 0.81 (0.67 to 0.98) | 0.84 (0.72 to 0.98) | 0.59 (0.46 to 0.77) |
| Steroid use at discharge | NS | NS | 1.17 (0.98 to 1.37) | NS |
| ECD | 1.37 (1.14 to 1.64) | – | 1.27 (1.11–1.47) | – |
| Transplant year | ||||
| 2000 to 2002 | 1.00 | 1.00 | 1.00 | 1.00 |
| 2003 to 2004 | NS | NS | NS | NS |
| 2005 to 2006 | NS | NS | NS | NS |
| 2007 to 2008 | 0.77 (0.57 to 1.04) | NS | NS | NS |
| *DGF | 1.53 (1.28 to 1.82) | 1.35 (1.12 to 1.62) | 1.58 (1.37 to 1.81) | 1.66 (1.40 to 1.97) |
Data presented as HR (95% CI) unless otherwise indicated.
a
Steroid use at discharge, CIT >36 hours, CIT unknown, DCD, PRA > 20%, PRA unknown, zero HLA mismatches, and dialysis duration unknown were NS (P > 0.10).
b
Steroid use at discharge and zero HLA mismatches were NS (P > 0.10).
c
Steroid use at discharge, diabetes mellitus cause of ESRD, DCD, CIT > 36 hours, CIT unknown, zero HLA mismatches, and dialysis duration unknown were NS (P > 0.10).
d
Steroid use at discharge and zero HLA mismatches were NS (P > 0.10).
*
DGF, dialysis in first week after transplantations.